Anrikefon (HSK21542) vs Difelikefalin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Kappa-opioid receptor (agonist, peripherally restricted) · full Chronic Kidney Disease pipeline

Anrikefon (HSK21542)

Marketed by Haisco Pharmaceutical Group

Phase 3 in Chronic Kidney Diseasepeptide
Reliable signal

NCT05135390 · Phase 3 · completed

This was a randomized, double-blinded, placebo-controlled trial with 545 patients and a validated itch-severity response endpoint. Anrikefon significantly outperformed placebo, with 37% of patients reaching a large itch improvement versus 15% on placebo (p<0.001).

Next expected readout: December 2027 · NCT07380113 (registry estimate)

Reported efficacy

Proportion of subjects with an improvement of ≥ 4 points from baseline in the weekly average of the daily Worst Itch Numeric Rating Scale (WI-NRS) after 12 weeks of treatment. (week 12): Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001) (met)

Result source: NCT05135390

Difelikefalin · Korsuva

Marketed by CSL Limited and partners

Approved in Chronic Kidney Diseasepeptide
Reliable signal

NCT03422653 · Phase 3 · completed

The trial randomized 378 participants equally to difelikefalin or placebo and was double-blinded for participants and investigators. Its primary clinical endpoint was met: 51.0% of patients receiving difelikefalin versus 27.6% receiving placebo achieved the specified improvement in itch intensity at week 12 (p<0.001).

Next expected readout: January 2027 · NCT07526324 (registry estimate)

Reported efficacy

Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5) (met)

Result source: NCT03636269

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointAnrikefon (HSK21542)Difelikefalin
Kidney composite outcome—Not posted · NCT05135390—Not reported
UACR, % change—Not posted · NCT05135390—Not reported
eGFR slope—Not posted · NCT05135390—Not reported
Haemoglobin, change—Not posted · NCT05135390—Not reported

Kidney composite outcome

Anrikefon (HSK21542)
—Not posted · NCT05135390
Difelikefalin
—Not reported

UACR, % change

Anrikefon (HSK21542)
—Not posted · NCT05135390
Difelikefalin
—Not reported

eGFR slope

Anrikefon (HSK21542)
—Not posted · NCT05135390
Difelikefalin
—Not reported

Haemoglobin, change

Anrikefon (HSK21542)
—Not posted · NCT05135390
Difelikefalin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Anrikefon (HSK21542): 0 of 4 rows · Difelikefalin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnrikefon (HSK21542)Difelikefalin
Dropout rate—
14.3%0.5mcg/kga
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 6 more results
—0.5 mcg/kg
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
12.3%0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
—0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
19.4%1 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
13.6%0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
13%0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
—0.5mcg/kga
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 6 more results
—0.5 mcg/kg
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
5.5%0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
—0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
—1 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
—0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
—0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
Serious AEs—
25.9%0.5mcg/kga
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 6 more results
53.4%0.5 mcg/kg
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
24.7%0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
32.6%0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
13.4%1 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
13.6%0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
13%0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
0.5mcg/kga
diarrhoea 9.5% (placebo 5.3%)
dizziness 6.9% (placebo 1.6%)
vomiting 5.3% (placebo 3.2%)
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 6 more results
0.5 mcg/kg
diarrhoea 19.5% (placebo 5.3%)
nausea 17.3% (placebo 4.8%)
fall 16% (placebo 4.3%)
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
0.5 mcg/kg
diarrhoea 7.7% (placebo 5.1%)
nausea 6.4% (placebo 4.2%)
vomiting 6.4% (placebo 5.5%)
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
0.5 mcg/kg
fall 13% (placebo 4.7%)
diarrhoea 11.3% (placebo 5.1%)
nausea 9.3% (placebo 4.2%)
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
1 mg
dizziness 7.5% (placebo 0%)
constipation 6% (placebo 3%)
diarrhoea 6% (placebo 1.5%)
NCT03617536 · Phase 2 · registry result, not featured evidence
0.5 mg
gastrooesophageal reflux disease 6.1% (placebo 0%)
constipation 3% (placebo 3%)
diarrhoea 3% (placebo 1.5%)
NCT03617536 · Phase 2 · registry result, not featured evidence
0.25 mg
fatigue 5.8% (placebo 1.5%)
hypertension 5.8% (placebo 1.5%)
hyperkalaemia 4.3% (placebo 6%)
NCT03617536 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Anrikefon (HSK21542)

Peak Pruritus NRS 4pt Improvement 37% vs 15% placebo @ 12wk
responder rate · % of participants
NCT05135390 · Phase 3 · sponsor-reported, not registry data

Difelikefalin

Itch NRS 3 51% (n=189) vs 27.6% (n=189) placebo @ 12wk0.5mcg/kg
responder rate · % of participants
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 1 more result
54% (n=237) vs 42.2% (n=236) placebo @ 12wk0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
Five D Itch Scale -6.97 vs -5.74 placebo score @ 12wk1 mg
absolute change · score
NCT03617536 · Phase 2 · registry result, not featured evidence
show 4 more results
-5 vs -3.7 placebo score @ 12wk0.5mcg/kg
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
-4.9 vs -3.8 placebo score @ 12wk0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
-6.84 vs -5.74 placebo score @ 12wk0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
-6.17 vs -5.74 placebo score @ 12wk0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
Skindex-10 -23.57 vs -19.95 placebo score @ 12wk1 mg
absolute change · score
NCT03617536 · Phase 2 · registry result, not featured evidence
show 4 more results
-17.2 vs -12 placebo score @ 12wk0.5mcg/kg
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
-16.6 vs -14.8 placebo score @ 12wk0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
-22.13 vs -19.95 placebo score @ 12wk0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
-21.19 vs -19.95 placebo score @ 12wk0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
Itch NRS ≥4 38.9% (n=189) vs 18% (n=189) placebo @ 12wk0.5mcg/kg
responder rate · % of participants
NCT03422653 · Phase 3 · Uremic Pruritus · phase 3
show 1 more result
41.2% (n=237) vs 28.4% (n=236) placebo @ 12wk0.5 mcg/kg
NCT03636269 · Phase 3 · Uremic Pruritus · phase 3
Worst Itch NRS -4.42 vs -3.32 placebo score @ 12wk1 mg
absolute change · score
NCT03617536 · Phase 2 · registry result, not featured evidence
show 2 more results
-3.84 vs -3.32 placebo score @ 12wk0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
-3.99 vs -3.32 placebo score @ 12wk0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
WI-NRS 3 Improvement 72.1% (n=67) vs 57.9% (n=67) placebo @ 12wk1 mg
responder rate · % of participants
NCT03617536 · Phase 2 · registry result, not featured evidence
show 2 more results
64.8% (n=66) vs 57.9% (n=67) placebo @ 12wk0.5 mg
NCT03617536 · Phase 2 · registry result, not featured evidence
66.2% (n=69) vs 57.9% (n=67) placebo @ 12wk0.25 mg
NCT03617536 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anrikefon (HSK21542)'s landscape · Difelikefalin's landscape